

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/046637 A2(51) International Patent Classification⁷: **A61K 9/00**Netherlands Cancer Institute), Plesmanlaan 121, NL-1066
CX Amsterdam (NL).(21) International Application Number:
PCT/IB2004/003886

(72) Inventors; and

(22) International Filing Date:
11 November 2004 (11.11.2004)(75) Inventors/Applicants (for US only): **VELDMAN**,
Robert, Jan [NL/NL]; Lis 18, NL-1273 CD Huizen (NL).
VAN BLITTERSWIJK, Wim, J. [NL/NL]; Burg. Vijl-
briefstraat 24, NL-1551 TK Westzaan (NL). **VERHEIJ**,
Marcel [NL/NL]; Von Bonninghausenlaan 38, NL-2161
ET Lisse (NL). **KONING**, Gerben, A. [NL/NL]; Stro-
camp 23, NL-3992 BR Houten (NL).



(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326642.6 14 November 2003 (14.11.2003) GB
0326759.8 17 November 2003 (17.11.2003) GB(74) Agents: **WYTENBURG**, Wilhelmus et al.; Mewburn El-
lis LLP, York House, 23 Kingsway, London Greater Lon-
don WC2B 6HP (GB).(71) Applicant (for all designated States except US): **HET**
NEDERLANDS KANKER INSTITUUT [NL/NL]; (The(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

[Continued on next page]

(54) Title: PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE



(57) Abstract: This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C₈-GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C₆-SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipid is selected from compounds of the following formula (I), wherein R¹ is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or R¹ is independently: an O-linked (optionally N-(C₁₋₄alkyl)-substituted amino)-C₁₋₆alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)C₁₋₆alkyl-phosphate group; R² is independently C₃₋₉alkyl, and is independently unsubstituted or substituted; R³ is independently C₇₋₁₉alkyl, and is independently unsubstituted or substituted; R⁴

[Continued on next page]



CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

is independently -H, -OH, or -O-C₁₋₄alkyl; R^N is independently -H or C₁₋₄alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R^S is -H; if the bond marked with an alpha (α) is a single bond, then R^S is -H or -OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxy-polyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE)). The present invention also pertains to methods for the preparation and use of such formulations.